Latest News and Press Releases

JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient...

Dyadic Provides Business Update Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive analysis of the...

JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...

Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...

Dublin, June 11, 2024 (GLOBE NEWSWIRE) -- The "Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin): Insights & Forecast (2024-2028)" report has been added to ...

JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building...

In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...